XEOMIN® (incobotulinumtoxinA) Receives European Approval for the Treatment of Chronic Sialorrhea in Children
Today, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, has been granted the use of XEOMIN® for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhea due to neurological / neurodevelopmental disorders on EU level.1 The national approvals of the country authorities involved will follow in the next weeks. The U.S. Food and Drug Administration granted approval in December 2020, and the Russian Federal Service for Surveillance in Healthcare in spring 2021.
Stefan Brinkmann, CEO Merz Therapeutics: “At Merz Therapeutics, we do everything to bring better outcomes to more patients. As XEOMIN® is already approved for the treatment of adult sialorrhea, we can now offer life-long treatment with our botulinum toxin A, staying a trusted partner for sialorrhea patients as well as their relatives and physicians for a lifetime.”
Dr. Marcus Gollub, President, Head of Region Europe complements: “Pediatric sialorrhea is a serious condition that can significantly impact not only the medical condition but also the quality of life of the children and their families. I am happy that with this new indication we are able to take care of the needs of those children suffering from drooling and contribute to a better life for them and their families.”
Sialorrhea, also known as drooling, is a symptom that occurs when excessive saliva accumulates in the mouth. It is a chronic impairment often seen in children with neurological disorders (e.g. cerebral palsy or traumatic brain injury) and/or intellectual disability or neurodegenerative diseases.
The approval by European authorities for the use of XEOMIN® for pediatric patients suffering from chronic sialorrhea, was achieved due to the convincing results of the SIPEXI study (Sialorrhea Pediatric Xeomin Investigation). It was a prospective, randomized, double-blind, placebo-controlled, multicenter phase III study with an extension phase evaluating the safety and efficacy of XEOMIN® in 255 children and adolescents aged 2 – 17 years up to 64 weeks. The study recently got published in Neurology, the premier peer-reviewed journal for clinical neurology research.2
XEOMIN® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm or hypersalivation. Merz uses state-of-the-art technology in its dedicated facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing. The highly purified 150kDa neurotoxin is the only active ingredient in XEOMIN®. It is produced by removing complexing proteins from botulinum toxin type A, using XTRACT® purification technology developed by Merz Pharma GmbH & Co. KGaA.
XEOMIN® is the registered trademark of Merz Pharma GmbH & Co. KGaA.
1
European SmPC (Summary of product characteristics), 2021-08-31
2
Berweck et al. Neurology. 2021 Aug 2:10.1212/WNL.0000000000012573. doi: 10.1212/WNL.0000000000012573.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs.
Please visit www.merz.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005540/en/
Contact information
Press Contact
Agnes Tesch
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH
Global Communications
+49 69 1503 2129
Agnes.tesch@merz.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thredd Becomes First Issuer-Processor to Offer Real Time Control over B2B Travel Payments through the Mastercard Wholesale Program12.8.2025 10:00:00 EEST | Press release
Thredd, a leading next-generation global issuer processor, today announced it has become the first to offer its travel agency customers real time payment control through new flexible product codes made possible through the Mastercard Wholesale Program (MWP). This new capability enables Thredd’s customers to better respond to supplier needs based on geography, product type and volume, while optimizing business-to-business travel payments through greater visibility, adaptability, and control. The MWP was designed to better support the global nature of the travel industry, offering greater security and predictability of cross-border payments between travel buyers and suppliers. Based on industry feedback, the Program has now evolved to provide real-time payment control, allowing issuers to seamlessly transition between product codes on a real-time basis. These product codes allow travel organizations to adapt virtual card technology in real time, based on supplier or product need. Thredd
500 Global Launches Sustainable Innovation Program Backed by Catalytic Partners12.8.2025 09:00:00 EEST | Press release
500 Global, one of the world’s most active venture capital firms1, announced today the launch of its Sustainable Innovation Program, an initiative designed to support mission-driven founders building commercially viable solutions to sustainability challenges across the global south. Rooted in the belief that the next generation of global growth will be driven by sustainable, inclusive innovation rooted in local leadership, the Sustainable Innovation Program brings together strategic capital, multilateral partnerships, and deep domain expertise to help entrepreneurs scale ventures that deliver both market returns and measurable impact. Their catalytic partner is the Shell Foundation, with co-funding from the UK Government as part of its Transforming Energy Access (TEA) platform and Catalysing Agriculture by Scaling Energy Ecosystems (CASEE) programme. This is the first of these partnerships focused on investing in human capital across agriculture, energy, mobility, and the built environ
Access Advance Video Distribution Patent Pool Gains Further Momentum with the Signing of Alibaba, ZTE, and Youku12.8.2025 03:00:00 EEST | Press release
Access Advance LLC today announced that Alibaba Group and ZTE Corporation have joined the Video Distribution Patent ("VDP") Pool as Licensors and Alibaba Group’s subsidiary Youku, one of China's leading video streaming platforms, has joined as a Licensee. The participation of these industry leaders strengthens the VDP Pool's comprehensive licensing solution by adding extensive patent portfolios, including significant contributions to both the HEVC/H.265 and the VVC/H.266 standard, while expanding coverage to Youku's massive user base. "We're delighted to welcome Alibaba, ZTE and Youku to the VDP Pool," said Peter Moller, CEO of Access Advance. "The addition of Alibaba and ZTE as Licensors brings critical intellectual property assets to the VDP Pool, while Youku's participation as a Licensee demonstrates the value of the pool's flexibility, predictable cost model, and simplified administration for major streaming platforms. They join other technology leaders including ByteDance, Kuaisho
First Cessna SkyCourier in Mongolia to Join Hunnu Air Fleet, Enhancing Operations in Asia-Pacific Region11.8.2025 17:00:00 EEST | Press release
The Cessna SkyCourier is making its entry into Mongolia with charter operator Hunnu Air placing the first order for the versatile twin-engine turboprop aircraft in the country. Hunnu Air will use the Cessna SkyCourier to enhance domestic tourism and cargo operations within Mongolia. The order includes two passenger variants of the Cessna SkyCourier aircraft and one Cessna Grand Caravan EX, with deliveries of their new aircraft expected to begin in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250811928514/en/ First Cessna SkyCourier in Mongolia to join Hunnu Air fleet, enhancing operations in Asia-Pacific region (Photo Credit: Textron Aviation) The Cessna SkyCourier is designed and produced by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. "Designed for versatility and performance, the Cessna SkyCourier is a strong fit to support Hunnu Air’s services across Mongolia,” said Lannie O’Bannion, senior vice pres
84% of Consumers Would Switch Banks Over Financial Crime Links, ThetaRay Report Finds11.8.2025 17:00:00 EEST | Press release
ThetaRay, a global leader in Cognitive AI financial crime compliance, today released its U.S. Banking & Fintech Trust Report 2025, offering new insights into consumer attitudes toward anti-money laundering (AML) practices. The report reveals that 84% of consumers would switch banks if linked to financial crime, and 87% would actively warn family and friends against using that institution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250811009362/en/ Brand reputation is one of a financial institution’s most valuable and vulnerable assets, built over years through trust, consistency, and significant investment. Encouragingly, 93% of respondents express either positive or neutral sentiments toward their current financial providers, suggesting a strong foundation of customer trust. But that trust is fragile: a single incident of financial crime can shatter a reputation overnight, triggering customer attrition, regulatory penal
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom